120 related articles for article (PubMed ID: 38042445)
1. Mef2c regulates bone mass through Sost-dependent and -independent mechanisms.
Morfin C; Sebastian A; Wilson SP; Amiri B; Murugesh DK; Hum NR; Christiansen BA; Loots GG
Bone; 2024 Feb; 179():116976. PubMed ID: 38042445
[TBL] [Abstract][Full Text] [Related]
2. Conditional Deletion of Sost in MSC-Derived Lineages Identifies Specific Cell-Type Contributions to Bone Mass and B-Cell Development.
Yee CS; Manilay JO; Chang JC; Hum NR; Murugesh DK; Bajwa J; Mendez ME; Economides AE; Horan DJ; Robling AG; Loots GG
J Bone Miner Res; 2018 Oct; 33(10):1748-1759. PubMed ID: 29750826
[TBL] [Abstract][Full Text] [Related]
3. Targeted deletion of Sost distal enhancer increases bone formation and bone mass.
Collette NM; Genetos DC; Economides AN; Xie L; Shahnazari M; Yao W; Lane NE; Harland RM; Loots GG
Proc Natl Acad Sci U S A; 2012 Aug; 109(35):14092-7. PubMed ID: 22886088
[TBL] [Abstract][Full Text] [Related]
4. Mef2c deletion in osteocytes results in increased bone mass.
Kramer I; Baertschi S; Halleux C; Keller H; Kneissel M
J Bone Miner Res; 2012 Feb; 27(2):360-73. PubMed ID: 22161640
[TBL] [Abstract][Full Text] [Related]
5. Analysis of SOST expression using large minigenes reveals the MEF2C binding site in the evolutionarily conserved region (ECR5) enhancer mediates forskolin, but not 1,25-dihydroxyvitamin D
St John HC; Hansen SJ; Pike JW
J Steroid Biochem Mol Biol; 2016 Nov; 164():277-280. PubMed ID: 26361013
[TBL] [Abstract][Full Text] [Related]
6. Control of the SOST bone enhancer by PTH using MEF2 transcription factors.
Leupin O; Kramer I; Collette NM; Loots GG; Natt F; Kneissel M; Keller H
J Bone Miner Res; 2007 Dec; 22(12):1957-67. PubMed ID: 17696759
[TBL] [Abstract][Full Text] [Related]
7. Effects of histone deacetylase inhibitor Scriptaid and parathyroid hormone on osteocyte functions and metabolism.
Sun N; Uda Y; Azab E; Kochen A; Santos RNCE; Shi C; Kobayashi T; Wein MN; Divieti Pajevic P
J Biol Chem; 2019 Jun; 294(25):9722-9733. PubMed ID: 31068415
[TBL] [Abstract][Full Text] [Related]
8. Skeletal Effects of Inducible ERα Deletion in Osteocytes in Adult Mice.
Doolittle ML; Saul D; Kaur J; Rowsey JL; Eckhardt B; Vos S; Grain S; Kroupova K; Ruan M; Weivoda M; Oursler MJ; Farr JN; Monroe DG; Khosla S
J Bone Miner Res; 2022 Sep; 37(9):1750-1760. PubMed ID: 35789113
[TBL] [Abstract][Full Text] [Related]
9. HDAC5 controls MEF2C-driven sclerostin expression in osteocytes.
Wein MN; Spatz J; Nishimori S; Doench J; Root D; Babij P; Nagano K; Baron R; Brooks D; Bouxsein M; Pajevic PD; Kronenberg HM
J Bone Miner Res; 2015 Mar; 30(3):400-11. PubMed ID: 25271055
[TBL] [Abstract][Full Text] [Related]
10. The YAP/TAZ transcriptional co-activators have opposing effects at different stages of osteoblast differentiation.
Xiong J; Almeida M; O'Brien CA
Bone; 2018 Jul; 112():1-9. PubMed ID: 29626544
[TBL] [Abstract][Full Text] [Related]
11. Co-deletion of Lrp5 and Lrp6 in the skeleton severely diminishes bone gain from sclerostin antibody administration.
Lim KE; Bullock WA; Horan DJ; Williams BO; Warman ML; Robling AG
Bone; 2021 Feb; 143():115708. PubMed ID: 33164872
[TBL] [Abstract][Full Text] [Related]
12. The Deletion of Hdac4 in Mouse Osteoblasts Influences Both Catabolic and Anabolic Effects in Bone.
Nakatani T; Chen T; Johnson J; Westendorf JJ; Partridge NC
J Bone Miner Res; 2018 Jul; 33(7):1362-1375. PubMed ID: 29544022
[TBL] [Abstract][Full Text] [Related]
13. Targeted postnatal knockout of Sclerostin using a bone-targeted adeno-associated viral vector increases bone anabolism and decreases canalicular density.
O'Donohue AK; Xiao Y; Lee LR; Schofield T; Cheng TL; Munns CF; Baldock PA; Schindeler A
Bone; 2023 Feb; 167():116636. PubMed ID: 36462771
[TBL] [Abstract][Full Text] [Related]
14. Constitutive protein kinase A activity in osteocytes and late osteoblasts produces an anabolic effect on bone.
Kao RS; Abbott MJ; Louie A; O'Carroll D; Lu W; Nissenson R
Bone; 2013 Aug; 55(2):277-87. PubMed ID: 23583750
[TBL] [Abstract][Full Text] [Related]
15. Global gene expression analysis identifies Mef2c as a potential player in Wnt16-mediated transcriptional regulation.
Sebastian A; Hum NR; Morfin C; Murugesh DK; Loots GG
Gene; 2018 Oct; 675():312-321. PubMed ID: 29981832
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein receptor-related protein 6 is required for parathyroid hormone-induced Sost suppression.
Li C; Wang W; Xie L; Luo X; Cao X; Wan M
Ann N Y Acad Sci; 2016 Jan; 1364(1):62-73. PubMed ID: 25847683
[TBL] [Abstract][Full Text] [Related]
17. Osteocyte network; a negative regulatory system for bone mass augmented by the induction of Rankl in osteoblasts and Sost in osteocytes at unloading.
Moriishi T; Fukuyama R; Ito M; Miyazaki T; Maeno T; Kawai Y; Komori H; Komori T
PLoS One; 2012; 7(6):e40143. PubMed ID: 22768243
[TBL] [Abstract][Full Text] [Related]
18. VEGFA From Early Osteoblast Lineage Cells (Osterix+) Is Required in Mice for Fracture Healing.
Buettmann EG; McKenzie JA; Migotsky N; Sykes DA; Hu P; Yoneda S; Silva MJ
J Bone Miner Res; 2019 Sep; 34(9):1690-1706. PubMed ID: 31081125
[TBL] [Abstract][Full Text] [Related]
19. Twist1 Inactivation in Dmp1-Expressing Cells Increases Bone Mass but Does Not Affect the Anabolic Response to Sclerostin Neutralization.
Lewis KJ; Choi RB; Pemberton EZ; Bullock WA; Firulli AB; Robling AG
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31505764
[TBL] [Abstract][Full Text] [Related]
20. VEGFA from osteoblasts is not required for lamellar bone formation following tibial loading.
McKenzie JA; Galbreath IM; Coello AF; Hixon KR; Silva MJ
Bone; 2022 Oct; 163():116502. PubMed ID: 35872107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
